Literature DB >> 25477595

Amantadine: multiple sclerosis-related fatigue.

Joyce A Generali1, Dennis J Cada2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2014        PMID： 25477595      PMCID： PMC4252198          DOI： 10.1310/hpj4908-710

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  6 in total

Review 1.  Amantadine for fatigue in multiple sclerosis.

Authors:  E Pucci; P Branãs; R D'Amico; G Giuliani; A Solari; C Taus
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 2.  Fatigue in multiple sclerosis - a brief review.

Authors:  Isuru Induruwa; Cris S Constantinescu; Bruno Gran
Journal:  J Neurol Sci       Date:  2012-08-27       Impact factor: 3.181

3.  Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study.

Authors:  Vahid Shaygannejad; Mohsen Janghorbani; Fereshteh Ashtari; Hasanali Zakeri
Journal:  Neurol Res       Date:  2012-09-12       Impact factor: 2.448

4.  Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.

Authors:  T Henze; P Rieckmann; K V Toyka
Journal:  Eur Neurol       Date:  2006-09-08       Impact factor: 1.710

Review 5.  Interventions for fatigue and weight loss in adults with advanced progressive illness.

Authors:  Cathy Payne; Philip J Wiffen; Suzanne Martin
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

6.  Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.

Authors:  Alenka Horvat Ledinek; Mojca Cizek Sajko; Uros Rot
Journal:  Clin Neurol Neurosurg       Date:  2013-12       Impact factor: 1.876
  6 in total
  5 in total

Review 1.  Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.

Authors:  Shumita Roy; Ralph H B Benedict; Allison S Drake; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

2.  Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis.

Authors:  Mojtaba Khazaei; Ashkan Karevan; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  Clin Transl Med       Date:  2019-07-01

Review 3.  New Strategies for Rehabilitation and Pharmacological Treatment of Fatigue Syndrome in Multiple Sclerosis.

Authors:  Ewa Zielińska-Nowak; Lidia Włodarczyk; Joanna Kostka; Elżbieta Miller
Journal:  J Clin Med       Date:  2020-11-07       Impact factor: 4.241

4.  Patterns and Outcomes of Complementary and Alternative Medicine Use Among Adult Patients With Multiple Sclerosis.

Authors:  Muhannad A Alnahdi; Abdullah K Alsulayhim; Ahmed H Bin Salem; Emad Masuadi; Yaser Al Malik
Journal:  Cureus       Date:  2020-10-06

Review 5.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.